MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Makes Elisrasib's ASCO 2026 Data So Significant

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Did D3 Bio Present at ASCO 2026 for Elisrasib

1 months ago

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

1 months ago

What Makes Roche's $700 Million Bet on Nurix So Significant

1 months ago

What Did Ascentage Pharma Present at ASCO 2026

1 months ago

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Erasca's ERAS-0015 showed 57% uORR in 2L KRAS G12X pancreatic cancer at 32 mg QD RDE, with 100% median relative dose intensity. Company plans registration-enabling lung cancer trial in H1 2027 and Pha...

ERAS

Stock News•1 months ago

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

Akeso’s ivonescimab plus chemotherapy demonstrated a 34% reduction in the risk of death (HR=0.66) compared to PD-1 plus chemotherapy in first-line sq-NSCLC patients. These landmark HARMONi-6 results w...

9926.HK

Stock News•1 months ago

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

Black Diamond Therapeutics reported steady response rates and CNS activity for silevertinib in EGFR-mutated NSCLC patients as of May 2026. While dose escalation continues, the company noted that durab...

BDTX

Stock News•2 months ago

Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out

Elicio Therapeutics faces a critical 2026 as it approaches a pivotal KRAS peptide vaccine trial readout. While the data could serve as a significant catalyst for the company, ongoing concerns regardin...

ELTX